Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Complement C3

Complement C3

Brief Information

Name:Complement C3
Target Synonym:Complement C3,Complement Component C3a,Epididymis Secretory Sperm Binding Protein Li 62p,C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1,C3bc,C3adesArg,C3,Complement Component C3b,Complement Component 3,C3a Anaphylatoxin,Prepro-C3,CPAMD1,Acylation-Stimulating Protein Cleavage Product,HEL-S-62p,AHUS5,ARMD9,ASP,C3a,C3b
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

 Complement C3 ELISA

Immobilized Cynomolgus Complement C3, His Tag (Cat. No. CO3-C52H5) at 1 μg/mL (100 μL/well) can bind Human Anti-C3,Human IgG1 Human Kappa with a linear range of 0.2-8 ng/mL (QC tested).

Complement C3 MALS images

The purity of Biotinylated Human Complement C3, His,Avitag (Cat. No. CO3-H82E8) is more than 85% and the molecular weight of this protein is around 165-200 kDa verified by SEC-MALS.

Synonym Name

Complement C3,CPAMD1


C3 is the major complement component serum. It is mainly synthesized by macrophages and liver. C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. It is cleaved into two fragments, C3a and C3b. C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pegcetacoplan APL-2 Approved Apellis Pharmaceuticals Inc Aspaveli, Empaveli United States Hemoglobinuria, Paroxysmal Apellis Pharmaceuticals Inc 2021-05-14 Motor Neuron Disease; Rejection of renal transplantation; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Lupus Nephritis; Thrombotic Microangiopathies; Glomerulonephritis, Membranoproliferative; Anemia, Hemolytic, Autoimmune; Geographic Atrophy; Amyotrophic Lateral Sclerosis; Glomerulonephritis; Macular Degeneration Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NGM-621 NGM-621 Phase 2 Clinical Ngm Biopharmaceuticals Inc Coronavirus Disease 2019 (COVID-19); Geographic Atrophy Details
Efdamrofusp alfa IBI-302 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration Details
Compstatin 40 AMY-101 Phase 2 Clinical University Of Pennsylvania Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Gingivitis Details
ARO-C3 ARO-C3; ARO-C-3 Phase 1 Clinical Arrowhead Pharmaceuticals Inc Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Glomerulonephritis Details
CG-001 CG-001 Phase 1 Clinical Chengdu Konjin Co Ltd Hemoglobinuria, Paroxysmal; Autoimmune Diseases Details
ALXN-1820 ALXN-1820 Phase 2 Clinical Alexion Pharmaceuticals Inc Anemia, Sickle Cell Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message